Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank21
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-264.47M
↓ 33% vs avg
Percentile
P21
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-198.19M
Historical baseline
PeriodValueYoY Change
TTM$-264.47M+41.2%
2024$-450.13M-24.9%
2023$-360.39M-23.9%
2022$-290.92M-20.5%
2021$-241.44M-19.7%
2020$-201.77M-140.7%
2019$-83.84M-156.3%
2018$-32.72M-5.3%
2017$-31.08M-23.4%
2016$-25.18M-